ABSORPTION, DISTRIBUTION AND EXCRETION OF LACIDIPINE, A DIHYDROPYRIDINE CALCIUM-ANTAGONIST, IN RAT AND DOG

被引:18
作者
PELLEGATTI, M [1 ]
GROSSI, P [1 ]
AYRTON, J [1 ]
EVANS, GL [1 ]
HARKER, AJ [1 ]
机构
[1] GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND
关键词
D O I
10.3109/00498259009046891
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The absorption, distribution and excretion of lacidipine have been studied in rat and dog after i.v. (0.05 mg/kg for rat; 0.5 mg/kg for dog) and oral dosage (2.5 mg/kg for rat; 2.0 mg/kg for dog). 2. Lacidipine was rapidly and extensively absorbed after oral dosing, in both species. Oral bioavailability was up to 26% in rat and up to 32% in dog, due to extensive first-pass metabolism. 3. After oral administration, peak levels of radioactivity were reached at 4-8 h in rat and 1-2 h in dog. Unchanged lacidipine peaked at 1-2 h in both species. Plasma levels of radioactivity were higher in female rats than in males but there was no difference in levels of unchanged drug. 4. After i.v. dosing the terminal half-life of unchanged drug was 2.9 h in rat and 8.2 h in dog. The half-life of radioactivity in plasma was longer in both species. 5. After both routes of administration, radioactivity was rapidly distributed in rat tissues with the highest concentration in liver, fat and gastrointestinal tract. Only traces of radioactivity were detected in the CNS and in rat foetuses. 6. Extensive biliary elimination occurred, and most of the radioactivity (73-95%) was excreted in the faeces after i.v. or oral administration. 7. The compound was extensively metabolized, no significant amount of unchanged drug was excreted in bile or urine. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:765 / 777
页数:13
相关论文
共 13 条
[1]  
ASLING J, 1972, FUNDAMENTALS DRUG ME, P94
[2]  
BAARNHIELM C, 1986, ACTA PHARMACOL TOX, V59, P113
[3]  
CARPI C, 1986, British Journal of Pharmacology, V89, p758P
[4]   FELODIPINE KINETICS IN HEALTHY-MEN [J].
EDGAR, B ;
REGARDH, CG ;
JOHNSSON, G ;
JOHANSSON, L ;
LUNDBORG, P ;
LOFBERG, I ;
RONN, O .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (02) :205-211
[5]   COMPARATIVE PHARMACOKINETICS OF NICARDIPINE HYDROCHLORIDE, A NEW VASODILATOR, IN VARIOUS SPECIES [J].
HIGUCHI, S ;
SHIOBARA, Y .
XENOBIOTICA, 1980, 10 (06) :447-454
[6]   ABSORPTION, EXCRETION AND METABOLISM OF A NEW DIHYDROPYRIDINE DIESTER CEREBRAL VASODILATOR IN RATS AND DOGS [J].
HIGUCHI, S ;
SASAKI, H ;
SHIOBARA, Y ;
SADO, T .
XENOBIOTICA, 1977, 7 (08) :469-479
[7]  
MARUHN D, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1781
[8]   METABOLISM AND PHARMACOKINETICS OF THE DIHYDROPYRIDINE CALCIUM-ANTAGONIST, RYOSIDINE, IN MAN [J].
MIDGLEY, I ;
CHASSEAUD, LF ;
TAYLOR, IW ;
WALMSLEY, LM ;
FOWKES, AG ;
DARRAGH, A ;
LAMBE, RF ;
BONN, R .
XENOBIOTICA, 1985, 15 (11) :965-977
[9]  
PARINOV VJ, 1985, ARZNEIMITTEL-FORSCH, V35-1, P808
[10]  
SUWELACK D, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1787